BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...million in milestones plus royalties. Oncoceutics’ lead product, ONC201, is in a pivotal trial for recurrent H3...
BioCentury | Dec 31, 2020
Distillery Therapeutics

Histamine receptor activation to treat anxiety and OCD

...nucleus accumbens reduced anxiety-like and OCD-like behaviors that were induced by acute restraint stress.TARGET/MARKER/PATHWAY: Histamine H3...
...Li, Nanjing University, Nanjing, Chinaemail: bli@nju.edu.cn CONTACT: Jing-Ning Zhu, same affiliation as aboveemail: jnzhu@nju.edu.cn. Claire Quang Nanjing University Histamine H3...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Sep 2, 2020
Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...with brain metastases, in cancer trials (see “FDA Encourages More Representative Cancer Trials”). TARGETSHRH3 – histamine H3...
BioCentury | Apr 11, 2020
Translation in Brief

ILIAS Biologics’ exosomes for sepsis; plus regulating cocaine seeking and a new COVID-19 target

...at Mount Sinai researchers have described a new epigenetic modification -- dopamine attachment to histone H3...
...more dopamine modifications in the midbrain of rats undergoing cocaine withdrawal. Midbrain overexpression of an H3...
...kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (p50) ILIAS Biologics Inc. Histone H3 Applied...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...of translational gene therapy at the rare disease research unit of Pfizer Inc. (NYSE:PFE). The H3...
...diagnose and treat patients with cancer or hereditary disorders. BioCentury Staff Gilead Sciences Inc. Adaptimmune Therapeutics plc Asklepios BioPharmaceutical Inc. H3...
BioCentury | Dec 4, 2019
Clinical News

Axsome plans Phase III trial for narcolepsy therapy following positive Phase II data

...Vaughn was principal at Wyatt Pharma Consulting. Targets: GHB - Gamma hydroxybutyrate; HRH3 - Histamine H3...
BioCentury | Nov 12, 2019
Company News

Skyhawk’s $80M Celgene deal expands remit to autoimmune

...December to develop splicing modifiers for cancer with Eisai Co. Ltd. (Tokyo:4523) and its subsidiary H3...
BioCentury | Nov 6, 2019

Peptide inhibitors of a histone chaperone for osteosarcoma and breast cancer

...Crystallographic analysis of ASF1A complexed with the histones H3 and H4 identified three residues on H3...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...down to pursue other opportunities. Schindler was VP, clinical development and executive medical director at H3...
Items per page:
1 - 10 of 262